Patents Assigned to Panion & BF Biotech Inc.
-
Patent number: 11883536Abstract: A method of preparing polylactic acid (PLA) microsphere and polylactic-co-glycolic acid (PLGA) microsphere is provided, including the following steps. A first solution is provided, including polylactic acid or polylactic-co-glycolic acid and an organic solvent. A second solution is provided, including polyvinyl alcohol, sodium carboxymethyl cellulose and an aqueous solution. The first solution is added to the second solution and, at the same time, the second solution is agitated until polylactic acid is solidified to form a plurality of polylactic acid microspheres, or until polylactic-co-glycolic acid is solidified to form a plurality of polylactic-co-glycolic acid microspheres. The polylactic acid microspheres or polylactic-co-glycolic acid microspheres are collected.Type: GrantFiled: March 31, 2021Date of Patent: January 30, 2024Assignees: TAIPEI MEDICAL UNIVERSITY, PANION & BF BIOTECH INC.Inventors: Ming-Thau Sheu, Yu-Ying Hsu, Yu-De Su, Yu-Hsuan Liu, Pu-Sheng Wei
-
Publication number: 20210199652Abstract: The present disclosure provides a test kit for simultaneously detecting a plurality of analytes, in which the test kit includes a lysis solution and a test strip. The lysis solution includes a salt, a surfactant, a stabilizer, and a buffer solution. The test strip includes a sample pad, a conjugation pad, a cellulose membrane, and a water-absorbing pad sequentially arranged on a support plate. The conjugation pad includes a conjugation pad solution and a plurality of antibody-conjugated microspheres, and the antibody-conjugated microspheres recognize plurality of analytes. The test kit of the present disclosure achieves an effect of simultaneously detecting more than or equal to four analytes even though the conjugation pad has a limited capacity of the antibody by preparing the lysis solution with appropriate ingredients and improving a formulation of the solution contained in the test strip.Type: ApplicationFiled: January 4, 2021Publication date: July 1, 2021Applicant: Panion & BF Biotech Inc.Inventors: Chun-Liang Shih, Chia-Hui Liu
-
Patent number: 10898459Abstract: The present invention discloses pharmaceutical-grade ferric organic compounds having enhanced dissolution rate. These ferric organic compounds, including but are not limited to ferric citrate, are useful for treating chronic kidney disease.Type: GrantFiled: November 16, 2017Date of Patent: January 26, 2021Assignee: Panion & BF Biotech Inc.Inventors: Keith Chan, Winston Town
-
Patent number: 9913821Abstract: The present invention discloses a novel form of ferric organic compounds, including a form of ferric citrate, which are soluble over a wider range of pH, and which have a large active surface area. The ferric organic compounds of the present invention can be delivered effectively by oral route with better delivery to treat patients suffering from hyperphosphatemia, metabolic acidosis and other disorders responsive to ferric organic compound therapy.Type: GrantFiled: May 2, 2016Date of Patent: March 13, 2018Assignee: Panion & BF Biotech Inc.Inventors: David W. K. Kwok, Nikolay Mintchev Stoynov
-
Patent number: 9889113Abstract: The present invention provides methods of treating soft tissue calcification in a subject, comprising a step of administering to said subject an effective amount of ferric organic compound, such as ferric citrate. The claimed methods may prevent, reverse, delay or stabilize soft tissue calcification in a subject having chronic kidney disease. Affected soft tissue calcification includes soft tissue calcification in the joint, skin, eye, in cardiovascular system such as heart valve, myocardium, coronary arteries and arteriole, or in internal organs such as kidney and lung.Type: GrantFiled: September 4, 2017Date of Patent: February 13, 2018Assignee: Panion & BF Biotech Inc.Inventors: Keith Chan, Winston Town, Shou Shan Chiang
-
Patent number: 9757416Abstract: The present invention discloses pharmaceutical-grade ferric organic compounds, including ferric citrate, which are soluble over a wider range of pH, and which have a large active surface area. A manufacturing and quality control process for making a pharmaceutical-grade ferric citrate that consistently complies with the established Manufacture Release Specification is also disclosed. The pharmaceutical-grade ferric organic compounds are suitable for treating disorders characterized by elevated serum phosphate levels.Type: GrantFiled: May 1, 2015Date of Patent: September 12, 2017Assignee: Panion & BF Biotech Inc.Inventors: Keith Chan, Winston Town, David W. K. Kwok, Nikolay Mintchev Stoynov
-
Patent number: 9539284Abstract: A method of selecting or determining a candidate compound suitable for use as a phosphate binder is disclosed. The candidate compound includes ferric compounds, ferric compound complexes, and their derivatives, salts, analogs, and metabolites. The effectiveness of the candidate compound as a phosphate binder is evaluated by a method, comprising measuring and correlating reduction of phosphate concentration in solution and reduction of phosphate absorption in cells.Type: GrantFiled: January 12, 2015Date of Patent: January 10, 2017Assignee: Panion & BF Biotech Inc.Inventor: Keith Chan
-
Patent number: 9328133Abstract: The present invention discloses a novel form of ferric organic compounds, including a form of ferric citrate, which are soluble over a wider range of pH, and which have a large active surface area. The ferric organic compounds of the present invention can be delivered effectively by oral route with better delivery to treat patients suffering from hyperphosphatemia, metabolic acidosis and other disorders responsive to ferric organic compound therapy.Type: GrantFiled: September 30, 2014Date of Patent: May 3, 2016Assignee: Panion & BF Biotech Inc.Inventors: David W. K. Kwok, Nikolay Mintchev Stoynov
-
Patent number: 9050316Abstract: The present invention discloses a pharmaceutical-grade ferric organic compounds, including ferric citrate, which are soluble over a wider range of pH, and which have a large active surface area. A manufacturing and quality control process for making a pharmaceutical-grade ferric citrate that consistently complies with the established Manufacture Release Specification is also disclosed. The pharmaceutical-grade ferric organic compounds are suitable for treating disorders characterized by elevated serum phosphate levels.Type: GrantFiled: June 17, 2014Date of Patent: June 9, 2015Assignee: Panion & BF Biotech Inc.Inventors: Keith Chan, Winston Town, David W. K. Kwok, Nikolay Mintchev Stoynov
-
Patent number: 8901349Abstract: The present invention discloses a novel form of ferric organic compounds, including a form of ferric citrate, which are soluble over a wider range of pH, and which have a large active surface area. The ferric organic compounds of the present invention can be delivered effectively by oral route with better delivery to treat patients suffering from hyperphosphatemia, metabolic acidosis and other disorders responsive to ferric organic compound therapy.Type: GrantFiled: August 27, 2013Date of Patent: December 2, 2014Assignee: Panion & BF Biotech Inc.Inventors: David W. K. Kwok, Nikolay Mintchev Stoynov
-
Patent number: 8846976Abstract: The present invention discloses a novel form of ferric organic compounds, including a form of ferric citrate, which are soluble over a wider range of pH, and which have a large active surface area. The ferric organic compounds of the present invention can be delivered effectively by oral route with better delivery to treat patients suffering from hyperphosphatemia, metabolic acidosis and other disorders responsive to ferric organic compound therapy.Type: GrantFiled: August 27, 2013Date of Patent: September 30, 2014Assignee: Panion & BF Biotech Inc.Inventors: David W. K. Kwok, Nikolay Mintchev Stoynov
-
Patent number: 8754258Abstract: The present invention discloses a novel form of ferric organic compounds, including a form of ferric citrate, which are soluble over a wider range of pH, and which have a large active surface area. The ferric organic compounds of the present invention can be delivered effectively by oral route with better delivery to treat patients suffering from hyperphosphatemia, metabolic acidosis and other disorders responsive to ferric organic compound therapy.Type: GrantFiled: August 27, 2013Date of Patent: June 17, 2014Assignee: Panion & BF Biotech Inc.Inventors: David W. K. Kwok, Nikolay Mintchev Stoynov
-
Patent number: 8754257Abstract: The present invention discloses a pharmaceutical-grade ferric organic compounds, including ferric citrate, which are soluble over a wider range of pH, and which have a large active surface area. A manufacturing and quality control process for making a pharmaceutical-grade ferric citrate that consistently complies with the established Manufacture Release Specification is also disclosed. The pharmaceutical-grade ferric organic compounds are suitable for treating disorders characterized by elevated serum phosphate levels.Type: GrantFiled: October 26, 2012Date of Patent: June 17, 2014Assignee: Panion & BF Biotech Inc.Inventors: Keith Chan, Winston Town
-
Publication number: 20140018420Abstract: The present invention discloses a novel form of ferric organic compounds, including a form of ferric citrate, which are soluble over a wider range of pH, and which have a large active surface area. The ferric organic compounds of the present invention can be delivered effectively by oral route with better delivery to treat patients suffering from hyperphosphatemia, metabolic acidosis and other disorders responsive to ferric organic compound therapy.Type: ApplicationFiled: August 27, 2013Publication date: January 16, 2014Applicant: Panion & BF Biotech, Inc.Inventors: David W.K. KWOK, Nikolay Mintchev Stoynov
-
Publication number: 20140011872Abstract: The present invention discloses a novel form of ferric organic compounds, including a form of ferric citrate, which are soluble over a wider range of pH, and which have a large active surface area. The ferric organic compounds of the present invention can be delivered effectively by oral route with better delivery to treat patients suffering from hyperphosphatemia, metabolic acidosis and other disorders responsive to ferric organic compound therapy.Type: ApplicationFiled: August 27, 2013Publication date: January 9, 2014Applicant: Panion & BF Biotech, Inc.Inventors: David W.K. KWOK, Nikolay Mintchev STOYNOV
-
Publication number: 20130345460Abstract: The present invention discloses a novel form of ferric organic compounds, including a form of ferric citrate, which are soluble over a wider range of pH, and which have a large active surface area. The ferric organic compounds of the present invention can be delivered effectively by oral route with better delivery to treat patients suffering from hyperphosphatemia, metabolic acidosis and other disorders responsive to ferric organic compound therapy.Type: ApplicationFiled: August 27, 2013Publication date: December 26, 2013Applicant: Panion & BF Biotech, Inc.Inventors: David W.K. KWOK, Nikolay Mintchev Stoynov
-
Patent number: 8609896Abstract: The present invention discloses a novel form of ferric organic compounds, including a form of ferric citrate, which are soluble over a wider range of pH, and which have a large active surface area. The ferric organic compounds of the present invention can be delivered effectively by oral route with better delivery to treat patients suffering from hyperphosphatemia, metabolic acidosis and other disorders responsive to ferric organic compound therapy.Type: GrantFiled: November 9, 2012Date of Patent: December 17, 2013Assignee: Panion & BF Biotech Inc.Inventors: David W. K. Kwok, Nikolay Mintchev Stoynov
-
Publication number: 20130079537Abstract: The present invention discloses a novel form of ferric organic compounds, including a form of ferric citrate, which are soluble over a wider range of pH, and which have a large active surface area. The ferric organic compounds of the present invention can be delivered effectively by oral route with better delivery to treat patients suffering from hyperphosphatemia, metabolic acidosis and other disorders responsive to ferric organic compound therapy.Type: ApplicationFiled: November 9, 2012Publication date: March 28, 2013Applicant: PANION & BF BIOTECH, INC.Inventor: Panon & BF Biotech, Inc.
-
Patent number: 8338642Abstract: The present invention discloses a novel form of ferric organic compounds, including a form of ferric citrate, which are soluble over a wider range of pH, and which have a large active surface area. The ferric organic compounds of the present invention can be delivered effectively by oral route with better delivery to treat patients suffering from hyperphosphatemia, metabolic acidosis and other disorders responsive to ferric organic compound therapy.Type: GrantFiled: February 24, 2010Date of Patent: December 25, 2012Assignee: Panion & BF Biotech, Inc.Inventors: David W. K. Kwok, Nikolay Mintchev Stoynov
-
Publication number: 20100217025Abstract: The present invention discloses a novel form of ferric organic compounds, including a form of ferric citrate, which are soluble over a wider range of pH, and which have a large active surface area. The ferric organic compounds of the present invention can be delivered effectively by oral route with better delivery to treat patients suffering from hyperphosphatemia, metabolic acidosis and other disorders responsive to ferric organic compound therapy.Type: ApplicationFiled: February 24, 2010Publication date: August 26, 2010Applicant: PANION & BF BIOTECH, INC.Inventors: David W.K. KWOK, Nikolay Mintchev STOYNOV